FindTrial
Sign In

DCC-2618

DRUG4 trials

Sponsors

Deciphera Pharmaceuticals, LLC, Zai Lab (Shanghai) Co., Ltd., Ono Pharmaceutical Co., Ltd.

Conditions

Advanced CancersAdvanced Systemic MastocytosisGastrointestinal Stromal Tumors

Phase 1

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
CompletedNCT02571036
Deciphera Pharmaceuticals, LLCAdvanced Cancers, Advanced Systemic Mastocytosis, Gastrointestinal Stromal Tumors
Start: 2015-11-30End: 2022-04-29Updated: 2023-12-13
Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments
RecruitingNCT07618377
Ono Pharmaceutical Co., Ltd.Gastrointestinal Stromal Tumors
Start: 2026-07-07End: 2028-02-01Target: 10Updated: 2026-07-20

Phase 2

A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
CompletedNCT04282980
Zai Lab (Shanghai) Co., Ltd.Gastrointestinal Stromal Tumors
Start: 2020-04-23End: 2022-08-23Updated: 2025-03-03

Phase 3

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
CompletedNCT03353753
Deciphera Pharmaceuticals, LLCGastrointestinal Stromal Tumors
Start: 2018-02-27End: 2022-05-11Updated: 2022-11-21

Related Papers

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors (GIST) as ≥4th line therapy: Long-term update from a single-arm, phase 2 trial.
Journal of Clinical Oncology2023-06-013 citations
Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
2023-01-234 citations
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial.
2022-12-135 citations
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor
Clinical Cancer Research2022-12-0912 citations
Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study.
2021-10-181 citations
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study
Clinical Cancer Research2021-09-0940 citations
Abstract CT123: Population pharmacokinetics of ripretinib in patients with advanced malignancies
Cancer Research2021-07-013 citations
Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.
Journal of Clinical Oncology2021-05-20
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
Journal of Clinical Oncology2020-08-1788 citations
Ripretinib (Qinlock™)
Oncology Times2020-08-142 citations
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
2020-06-05260 citations
Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.
Journal of Clinical Oncology2020-05-2010 citations
Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.
Journal of Clinical Oncology2020-05-204 citations
Abstract C077: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)
Molecular Cancer Therapeutics2019-12-013 citations
Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens
Annals of Oncology2018-10-0122 citations
Abstract CT029: Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST)
Cancer Research2018-07-013 citations
Abstract 3925: Inhibition of oncogenic and drug-resistant PDGFRA and KIT alterations by DCC-2618
Cancer Research2018-07-01
Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.
Journal of Clinical Oncology2018-05-205 citations
Abstract LB-039: Translational research in a phase I proof-of-concept study supports that DCC-2618 is a pan-KIT inhibitor
Cancer Research2017-07-01
Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors.
Journal of Clinical Oncology2017-05-206 citations